Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27308480 | 0.89 | MAPT (0.56) | MAPTGAAPOLBLMNATSHR | |
| SCHEMBL14916456 | 0.86 | MAPT (0.53) | MAPTGAAPOLBLMNATSHR | |
| SCHEMBL27475536 | 0.86 | MAPT (0.53) | MAPTGAAPOLBLMNATSHR | |
| SCHEMBL8033801 | 0.86 | MAPT (0.72) | MAPTGAAPOLBLMNATSHR | |
| SCHEMBL8611045 | 0.84 | ALDH1A1 (0.52) | MAPTGAAPOLBALDH1A1MEN1 | |
| SCHEMBL343289 | 0.84 | LTA4H (0.50) | MAPTGAAPOLBLMNAALDH1A1 | |
| SCHEMBL8037904 | 0.84 | MAPT (0.69) | MAPTGAAPOLBLMNATSHR | |
| SCHEMBL4851027 | 0.82 | MAPT (0.54) | MAPTGAAPOLBLMNAMAPK1 | |
| SCHEMBL1741449 | 0.81 | MAPT (0.61) | MAPTGAAPOLBLMNATSHR | |
| SCHEMBL15793447 | 0.80 | MAPT (0.50) | MAPTGAAPOLBLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102648203-B | Iridium complex, organic electroluminescent device and uses thereof | SAMSUNG ELECTRONICS CO.,LTD. (KR) | 2015-09-30 | — | — | CN | disclosed |
| EP-2508527-B1 | IRIDIUM COMPLEX COMPOUND, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND USES THEREOF | SAMSUNG ELECTRONICS CO LTD (KR) | 2015-01-07 | — | — | EP | disclosed |
| EP-2508527-A1 | IRIDIUM COMPLEX COMPOUND, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND USE THEREFOR | Showa Denko K.K. (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-20120235132-A1 | IRIDIUM COMPLEX COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT, AND USES THEREOF | SAMSUNG ELECTRONICS CO., LTD (KR) | 2012-09-20 | — | — | US | disclosed |
| EP-1338599-B1 | Optically pure analogues of Camptothecin | SOD CONSEILS RECH APPLIC (FR) | 2007-02-14 | — | — | EP | disclosed |
| US-7135478-B2 | Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2006-11-14 | — | — | US | disclosed |
| US-7012079-B1 | Optically pure camptothecin analogues | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2006-03-14 | — | — | US | disclosed |
| US-20050038064-A1 | Anticarcinogenic agents; breast, colon, lung, prostate, ovarian, and gastric cancers, leukemia, melanomas; (5R)-5-ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2005-02-17 | — | — | US | disclosed |
| US-6815546-B2 | ANTICANCER AGENTS | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-11-09 | — | — | US | disclosed |
| EP-1338599-A1 | Optically pure analogues of Camptothecin | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2003-08-27 | — | — | EP | disclosed |
| EP-1165565-B1 | OPTICALLY PURE CAMPTOTHECIN ANALOGUES | SOD CONSEILS RECH APPLIC (FR) | 2003-06-04 | — | — | EP | disclosed |
| US-20030004150-A1 | New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | IPSEN PHARMA S.A.S. (FR) | 2003-01-02 | — | — | US | disclosed |
| EP-1165565-A1 | OPTICALLY PURE CAMPTOTHECIN ANALOGUES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000050427-A1 | OPTICALLY PURE CAMPTOTHECIN ANALOGUES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004150-A1 | New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | TOP1, TOP2A, TYMP | MAPT 4181/4885GAA 1683/4885POLB 691/4885 |
| US-20120235132-A1 | IRIDIUM COMPLEX COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT, AND USES THEREOF | ELP1, AGO2, IPO5 | MAPT 1887/4885GAA 2067/4885POLB 2507/4885 |
| US-20050038064-A1 | Anticarcinogenic agents; breast, colon, lung, prostate, ovarian, and gastric cancers, leukemia, melanomas; (5R)-5-ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione | MCL1, BRCA1, API5 | MAPT 4618/4885GAA 3903/4885POLB 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.